Research involving minors or other incompetent subjects is ethically complex, particularly if the research does not directly benefit the subjects. Thus, many guidelines and regulations state that incompetent research subjects must not be included in such research unless it entails minimal risk and minimal burden. The new EU Clinical Trials Regulation adds the following to this well-known requirement: ‘in comparison with the standard treatment of the subjects’ condition’. In this paper, I argue that this addition can be interpreted in different ways. According to one of the possible interpretations, it means that research risks and burdens can be regarded as minimal for a certain group of subjects if they are comparable to those that the subjects have to undergo when being treated for their conditions. As the standard treatments of many conditions are quite risky and burdensome, this interpretation allows for research with risks and burdens far exceeding the level usually regarded as minimal, without explicitly saying so. This is worrisome, because such a lack of clarity may compromise thorough review and valid informed consent procedures and consequently may lead to exploitation of these vulnerable groups. If Europe wants to allow for exceptions to the minimal risk and burden requirement, it should explicitly acknowledge this step as such and accurately formulate in which cases such exceptions are justified.
- Clinical trials
- Research Ethics
- Research on Special Populations
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Read the full text or download the PDF:
Other content recommended for you
- Improving the Helsinki Declaration's guidance on research in incompetent subjects
- Acceptable risks and burdens for children in research without direct benefit: a systematic analysis of the decisions made by the Dutch Central Committee
- Drug development for children: how adequate is the current European ethical guidance?
- To stop or not to stop: dissent and undue burden as reasons to stop participation in paediatric research
- Are positive experiences of children in non-therapeutic research justifiable research benefits?
- Non-therapeutic research with minors: how do chairpersons of German research ethics committees decide?
- Assessing research risks systematically: the net risks test
- Informed consent for functional MRI research on comatose patients following severe brain injury: balancing the social benefits of research against patient autonomy
- Process of risk assessment by research ethics committees: foundations, shortcomings and open questions
- Abortion decisions as inclusion and exclusion criteria in research involving pregnant women and fetuses